Total adverse events · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in total adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes total Adverse Events compared with placebo or Control (very low certainty).
1 finding from 1 review
Total adverse events · acute gout
High‐dose colchicine may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
Total adverse events · acute gout
High‐dose may leads to higher total adverse events compared with low‐dose colchicine (low certainty).
1 finding from 1 review
Total adverse events · acute gout
Low‐dose colchicine showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Total adverse events · participants with tophi in gout
Monthly pegloticase showed no clear difference in total adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events · participants with tophi in gout
Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in total adverse events compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).
1 finding from 1 review
Total adverse events · participants with tophi in gout
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in total adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
1 finding from 1 review
Total adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) showed no clear difference in total adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events · acute gout
Non‐selective NSAIDs probably leads to higher total adverse events compared with selective cyclo‐oxygenase‐2 inhibitors (moderate certainty).
1 finding from 1 review
RR 1.94 [1.36, 2.78]
Studies not reported
Moderate
Total adverse events · acute gout
NSAIDs probably leads to higher total adverse events compared with glucocorticoids (moderate certainty).
1 finding from 1 review
RR 1.62 [1.03, 2.55]
Studies not reported
Moderate
Total adverse events · acute gout
NSAIDs showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 0.2 [0.01, 3.85]
Studies not reported
Low
Total adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Total adverse events · glabellar lines
Summary of Findings Table ‐ IncobotulinumtoxinA 20U showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review